In a September editorial in Nature Biotechnology Ruslan Dorfman accused 23andMe of being part of a global conspiracy to monopolize the consumer genetics industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

23andMe's Data Deal

23andMe Gets a Grant

Then Again

Going Well

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.